Cardior bags €64m in Series B FinancingCardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure. more ➔
Yet another blow to Mercks cancer hopefu...GSK-partnered Merck is throwing in the towel for a Phase II trial of its immunotherapy contender bintrafusp alfa after disappointing results. more ➔
Beckley Psytech: €68m for psychedelic me...UK-based start-up Beckley Psytech has completed an upsized Series B financing, raising €68m (US$80m). Proceeds will go towards the companys pipeline of psychedelic compounds dedicated to addressing … more ➔
ERS Genomics and Cellular Engineering Tech...ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement. more ➔
Boehringer walks away from CureVac dealSetback for CureVac: Boehringer Ingelheim halts a 7-year-old €500m lung cancer collaboration with the Tübingen-based biopharmaceutical company. more ➔
New vaccine trial targets Covid variantsVaccine maker Valneva SE announced the initiation of a further Phase III trial for its COVID-19 vaccine candidate VLA2001. more ➔
Visus Therapeutics cashes in €20m from L...Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia more ➔
Protein may help control cancer cellsThe protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find. more ➔
British drug developer Mission Therapeutic...British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration. more ➔
Bayer takes over VividionThe big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics. more ➔
